Idiopathic Pulmonary Fibrosis – Epidemiology – Americas

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of IPF for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s IPF forecast will answer the following questions:

• Of all people diagnosed with IPF, how many in each country across the developed world are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of IPF over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 11 IPF patient populations, as follows:

• Diagnosed IPF incident cases.
• Diagnosed IPF prevalent cases.
• Diagnosed stage 1 IPF prevalent cases.
• Diagnosed stage 2 IPF prevalent cases.
• Diagnosed stage 3 IPF prevalent cases.
• Diagnosed IPF prevalent cases with gastroesophageal reflux disease
• Diagnosed IPF prevalent cases with emphysema.
• Diagnosed IPF prevalent cases with pulmonary hypertension.
• Diagnosed IPF prevalent cases with obstructive sleep apnea.
• Diagnosed drug-treated IPF prevalent cases.
• Diagnosed non-drug-treated IPF prevalent cases.

Note: Coverage may vary by country.